|
|
|
|
| LEADER |
00000cam a2200000Mu 4500 |
| 001 |
EBSCO_on1260344035 |
| 003 |
OCoLC |
| 005 |
20231017213018.0 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
210717s2021 xx o ||| 0 eng d |
| 040 |
|
|
|a EBLCP
|b eng
|c EBLCP
|d N$T
|d OCLCF
|d OCLCQ
|d OCLCO
|
| 020 |
|
|
|a 9814998095
|
| 020 |
|
|
|a 9789814998093
|q (electronic bk.)
|
| 035 |
|
|
|a (OCoLC)1260344035
|
| 050 |
|
4 |
|a RM267
|
| 082 |
0 |
4 |
|a 616.90461
|2 23
|
| 049 |
|
|
|a UAMI
|
| 100 |
1 |
|
|a Atta-ur-Rahman.
|
| 245 |
1 |
0 |
|a Frontiers in Clinical Drug Research - Anti Infectives
|h [electronic resource].
|
| 260 |
|
|
|a Sharjah :
|b Bentham Science Publishers,
|c 2021.
|
| 300 |
|
|
|a 1 online resource (194 p.).
|
| 490 |
1 |
|
|a Frontiers in Clinical Drug Research - Anti Infectives Ser.
|
| 500 |
|
|
|a Description based upon print version of record.
|
| 505 |
0 |
|
|a Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Preface -- List of Contributors -- Nucleic Acid and Peptide Aptamers as Potential Antiviral Drugs -- Serap Evran1,*, Özge Uğurlu1,2, Ezgi Man1, Merve Gültan1 and Canan Özyurt3 -- 1. INTRODUCTION -- 1.1. The in vitro Selection Methods for Peptide and Nucleic Acid Aptamers -- 1.2. MRNA Display -- 1.3. Ribosome Display -- 1.4. SELEX (Systematic Evolution of Ligands by Exponential Enrichment) for Nucleic Acid Aptamers -- 1.4.1. Cell-SELEX -- 1.4.2. Bead-Based SELEX -- 1.5. Post-SELEX Modifications
|
| 505 |
8 |
|
|a 1.6. Modification of Peptide Aptamers for Therapeutic Applications -- 2. APTAMERS IN VIRAL DIAGNOSIS -- 2.1. Aptamers in Diagnosis of Hepatitis B Virus (HBV) -- 2.2. Aptamers in Diagnosis of Hepatitis C Virus (HCV) -- 2.3. Aptamers in Diagnosis of Human Immunodeficiency Virus (HIV) -- 2.4. Aptamers in Diagnosis of Influenza -- 2.5. Aptamers in Diagnosis of Arboviruses -- 2.6. Aptamers in Diagnosis of SARS Virus -- 2.7. Aptamers in Diagnosis of Ebola Virus -- 2.8. Aptamer in Diagnosis of SARS-COV-2 -- 2.9. Aptamers in Diagnosis of Human Papilloma Virus (HPV)
|
| 505 |
8 |
|
|a 2.10. Aptamer in Diagnosis of Herpes Simplex Virus (HSV) -- 3. POTENTIALLY THERAPEUTIC APTAMERS AGAINST VIRAL PROTEINS -- 3.1. Aptamers Against Human Immunodeficiency Virus (HIV) Proteins -- 3.1.1. Reverse Transcriptase (RT) -- 3.1.2. Integrase (IN) -- 3.1.3. Other proteins of HIV-1 -- 3.2. Aptamers Against Hepatitis C Virus (HCV) Proteins -- 3.2.1. Non-Structural Proteins (NS) of HCV -- 3.2.2. Structural Proteins of HCV -- 3.3. Aptamers Against Hepatitis B Virus (HBV) Proteins -- 3.4. Aptamers Against Severe Acute Respiratory Syndrome (SARS) Coronavirus Proteins
|
| 505 |
8 |
|
|a 3.5. Aptamers Against Influenza Virus Proteins -- 4. CONCLUDING REMARKS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Host-Directed, Antibiotic-Adjuvant Combination, and Antibiotic-Antibiotic Combination for Treating Multidrug-Resistant (MDR) Gram-Negative Pathogens -- Wattana Leowattana1,*, Pathomthep Leowattana2 and Tawithep Leowattana3 -- INTRODUCTION -- MDR GRAM-NEGATIVE PATHOGENS (GNPS) -- MECHANISM OF RESISTANT DRUGS -- ESBL-PRODUCING ENTEROBACTERIACEAE -- CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE) -- MDR A. BAUMANNII -- HOST-DIRECTED THERAPIES
|
| 505 |
8 |
|
|a ANTIBIOTIC-ADJUVANT COMBINATION THERAPY -- ANTIBIOTIC-ANTIBIOTIC COMBINATION THERAPY -- TREATMENT OF MDR K. PNEUMONIAE -- TREATMENT OF MDR P. AERUGINOSA -- TREATMENT OF MDR A. BAUMANNII -- TREATMENT OF MDR E. COLI -- CONCLUDING REMARKS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Bioactive Substances as Anti-infective Strategies Against Clostridioides Difficile -- Joana Barbosa1,* and Paula Teixeira1 -- INTRODUCTION -- PATHOGENESIS AND EPIDEMIOLOGY OF C. DIFFICILE -- CURRENT APPROACHES IN THE TREATMENT OF CDI -- Initial Episodes of CDI
|
| 500 |
|
|
|a Fulminant Episodes of CDI.
|
| 590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
| 650 |
|
0 |
|a Anti-infective agents.
|
| 650 |
|
0 |
|a Clinical medicine.
|
| 650 |
|
0 |
|a Medical innovations.
|
| 650 |
|
2 |
|a Anti-Infective Agents
|
| 650 |
|
2 |
|a Clinical Medicine
|
| 650 |
|
6 |
|a Antiinfectieux.
|
| 650 |
|
6 |
|a Médecine clinique.
|
| 650 |
|
6 |
|a Médecine
|x Innovations.
|
| 650 |
|
7 |
|a Anti-infective agents
|2 fast
|
| 650 |
|
7 |
|a Clinical medicine
|2 fast
|
| 650 |
|
7 |
|a Medical innovations
|2 fast
|
| 776 |
0 |
8 |
|i Print version:
|a Atta-ur-Rahman
|t Frontiers in Clinical Drug Research - Anti Infectives: Volume 7
|d Sharjah : Bentham Science Publishers,c2021
|z 9789814998109
|
| 830 |
|
0 |
|a Frontiers in Clinical Drug Research - Anti Infectives Ser.
|
| 856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=2962575
|z Texto completo
|
| 938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL6676571
|
| 938 |
|
|
|a EBSCOhost
|b EBSC
|n 2962575
|
| 994 |
|
|
|a 92
|b IZTAP
|
